Email

mamonkin@bcm.edu

Positions

Assistant Professor

Pathology & Immunology
Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX US

Member

Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas United States

Education

PhD from Baylor College of Medicine

10/2013 - Houston, Texas United States

Professional Interests

• Immunobiology of chimeric antigen receptor (CAR) T cells
• Adoptive T cell therapy of cancer and autoimmune diseases
• Clinical trials of CAR T cells in hematologic malignancies
• Synthetic biology in cell therapies

Professional Statement

The main research interest of my laboratory is studying immunobiology of T-cells engineered with chimeric antigen receptors (CARs) and creating new cell therapies for devastating diseases. We investigate molecular mechanisms regulating the activity of CAR T-cells and develop new strategies for clinical translation. In particular, we are utilizing protein engineering and genome editing to create T-cell therapies against T-cell malignancies (T-ALL, T-cell lymphoma) with minimal damage to normal lymphocytes. We are also exploring new strategies to target pathogenic T-cells in the context of immune rejection and allo/autoimmune diseases. These therapies are being evaluated in Phase I clinical trials at BCM (NCT03081910, NCT03690011, NCT04219163).

Websites

Selected Publications

• Mo F, Watanabe N, McKenna MK, Hicks MJ, Srinivasan M, Gomes-Silva D, Atilla E, Smith T, Ataca Atilla P, Ma R, Quach D, Heslop HE, Brenner MK, Mamonkin M. "Engineered off-the-shelf therapeutic T cells resist host immune rejection." Nat Biotechnol. 2021 Jan 1; Pubmed PMID: 32661440
• Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, Rouce RH, Bao G, Brenner MK, Mamonkin M "CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.." Blood. 2017 Jul; Pubmed PMID: 28539325
• Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, Sritabal-Ramirez J, Hu H, Wang S, Mehta B, Srinivasan M, Scherer LD, Zhang H, Thakkar SG, Hill LC, Heslop HE, Cheng C, Brenner MK, Mamonkin M. "Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T-cells for T-cell malignancies.." Mol Ther. 2022 Sep 9; Pubmed PMID: 36086817
• Mo F, Watanabe N, Ingersoll Omdahl K, Burkhardt PM, Ding X, Hayase E, Panoskaltsis-Mortari A, Jenq RR, Heslop HE, Kean LS, Brenner MK, Tkachev V, Mamonkin M. "Engineering T cells to suppress acute GvHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation.." Blood. 2022 Aug 31; Pubmed PMID: 36044667

Funding

P50 SPORE IN LYMPHOMA (2017-2027)

NIH

High Impact High Reward (2021-2023)

CPRIT

SCOR (2019-2023)

Leukemia and Lymphoma Society

Dream Team in T-cell Lymphoma

Stand Up to Cancer (2019-2023)